Does long-term use of antidiabetic drugs changes cancer risk?
| Title: | Does long-term use of antidiabetic drugs changes cancer risk? |
|---|---|
| Authors: | Liu YC; Division of Nephrology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung City.; Nguyen PA; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Humayun A; Department of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Shaikh Zayed Medical Complex, Lahore, Pakistan.; Chien SC; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; International Center for Health Information Technology (ICHIT).; Yang HC; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; International Center for Health Information Technology (ICHIT).; Asdary RN; Masters Program in Global Health & Department, College of Public Health, Taipei Medical University, Taipei.; Syed-Abdul S; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; International Center for Health Information Technology (ICHIT).; Hsu MH; Graduate Institute of Data Science.; Research Center of Artificial Intelligence in Medicine and Health (TAIMH), Taipei Medical University, Taipei, Taiwan.; Moldovan M; South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia.; Yen Y; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University.; Taipei Medical University Research Center of Cancer Translational Medicine.; Li YJ; Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; International Center for Health Information Technology (ICHIT).; Research Center of Artificial Intelligence in Medicine and Health (TAIMH), Taipei Medical University, Taipei, Taiwan.; Department of Dermatology, Wan Fang Hospital.; Jian WS; School of Health Care Administration, Taipei Medical University, Taipei, Taiwan.; Faculty of Health Sciences, Macau University of Science and Technology, Macau.; Iqbal U; Department of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Shaikh Zayed Medical Complex, Lahore, Pakistan.; International Center for Health Information Technology (ICHIT).; Masters Program in Global Health & Development Department, PhD Program in Global Health and Health Security, College of Public Health, Taipei Medical University, Taipei, Taiwan. |
| Source: | Medicine [Medicine (Baltimore)] 2019 Oct; Vol. 98 (40), pp. e17461. |
| Publication Type: | Journal Article; Observational Study |
| Language: | English |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins |
| MeSH Terms: | Hypoglycemic Agents/*administration & dosage ; Neoplasms/*epidemiology; Aged ; Case-Control Studies ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Incidence ; Logistic Models ; Male ; Middle Aged ; Odds Ratio ; Proportional Hazards Models ; Risk Factors ; Taiwan |
| Abstract: | Antidiabetic medications are commonly used around the world, but their safety is still unclear. The aim of this study was to investigate whether long-term use of insulin and oral antidiabetic medications is associated with cancer risk.We conducted a well-designed case-control study using 12 years of data from Taiwan's National Health Insurance Research Database and investigated the association between antidiabetic medication use and cancer risk over 20 years. We identified 42,500 patients diagnosed with cancer and calculated each patient's exposure to antidiabetic drugs during the study period. We matched cancer and noncancer subjects matched 1:6 by age, gender, and index date, and used Cox proportional hazard regression and conditional logistic regression, adjusted for potential confounding factors, that is, medications and comorbid diseases that could influence cancer risk during study period.Pioglitazone (adjusted odds ratio [AOR], 1.20; 95% confidence interval [CI], 1.05-1.38); and insulin and its analogs for injection, intermediate or long acting combined with fast acting (AOR, 1.22; 95% CI, 1.05-1.43) were significantly associated with a higher cancer risk. However, metformin (AOR, 1.00; 95% CI, 0.93-1.07), glibenclamide (AOR, 0.98; 95% CI, 0.92-1.05), acarbose (AOR, 1.06; 95% CI, 0.96-1.16), and others do not show evidence of association with cancer risk. Moreover, the risk for specific cancers among antidiabetic users as compared with nonantidiabetic medication users was significantly increased for pancreas cancer (by 45%), liver cancer (by 32%), and lung cancer (by 18%).Antidiabetic drugs do not seem to be associated with an increased cancer risk incidence except for pioglitazone, insulin and its analogs for injection, intermediate or long acting combined with fast acting. |
| References: | Health Aff (Millwood). 2003 May-Jun;22(3):77-88. (PMID: 12757274); Oncogene. 2008 Jun 5;27(25):3576-86. (PMID: 18212742); Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. (PMID: 20947488); Diabetologia. 2009 Sep;52(9):1745-54. (PMID: 19588120); Pharmacoepidemiol Drug Saf. 2007 May;16(5):485-92. (PMID: 17192841); Diabetes Care. 2013 Jun;36(6):1569-76. (PMID: 23300288); Diabetologia. 2011 Sep;54(9):2254-62. (PMID: 21614572); Cochrane Database Syst Rev. 2014 Apr 29;(4):MR000034. (PMID: 24782322); Postgrad Med. 2010 May;122(3):158-65. (PMID: 20463425); Lancet. 2005 Oct 8;366(9493):1279-89. (PMID: 16214598); Diabetes. 2010 May;59(5):1254-60. (PMID: 20185812); J Intern Med. 2015 Feb;277(2):235-247. (PMID: 25418285); Am J Gastroenterol. 2012 Apr;107(4):620-6. (PMID: 22290402); Diabetologia. 2009 Sep;52(9):1755-65. (PMID: 19603149); J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716); Carcinogenesis. 2015 Sep;36(9):971-81. (PMID: 26025909); Gastroenterology. 2009 Aug;137(2):482-8. (PMID: 19375425); N Engl J Med. 2007 Jun 14;356(24):2457-71. (PMID: 17517853); BMJ. 2005 Jun 4;330(7503):1304-5. (PMID: 15849206); Acta Oncol. 2012 Mar;51(3):400-2. (PMID: 22497435); Lancet. 2014 Jun 7;383(9933):1947-8. (PMID: 24910221); N Engl J Med. 2000 Jun 22;342(25):1887-92. (PMID: 10861325); Diabetes Care. 2009 Sep;32(9):1620-5. (PMID: 19564453); Diabetes Care. 2013 Feb;36(2):369-75. (PMID: 23043163); Diabetologia. 2009 Dec;52(12):2499-506. (PMID: 19756478); JAMA Intern Med. 2015 Sep;175(9):1527-9. (PMID: 26192815); Diabetes Care. 2011 Jun;34(6):1369-71. (PMID: 21515844); Cancer Res. 2007 Jul 15;67(14):6745-52. (PMID: 17638885); Gastroenterology. 2011 Jul;141(1):150-6. (PMID: 21334333); Br J Clin Pharmacol. 2013 May;75(5):1356-64. (PMID: 23043261); Diabetes Care. 2011 Apr;34(4):923-9. (PMID: 21447664); Diabetologia. 2009 Sep;52(9):1732-44. (PMID: 19565214); Diabetologia. 2009 Sep;52(9):1766-77. (PMID: 19572116); Am J Epidemiol. 2008 Oct 15;168(8):925-31. (PMID: 18700234); Medicine (Baltimore). 2015 Feb;94(6):e483. (PMID: 25674736); BMC Med. 2007 Jun 21;5:17. (PMID: 17584937) |
| Substance Nomenclature: | 0 (Hypoglycemic Agents) |
| Entry Date(s): | Date Created: 20191003 Date Completed: 20191014 Latest Revision: 20191114 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6783244 |
| DOI: | 10.1097/MD.0000000000017461 |
| PMID: | 31577776 |
| Database: | MEDLINE |
Journal Article; Observational Study